Comorbidity of diabetes mellitus and hypertension in the clinical setting: A review of prevalence, pathophysiology, and treatment perspectives

Clinical Therapeutics

Volumn 29, Issue SUPPL. B, 2007, Pages

  Bretzel, Reinhard G ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

diabetes mellitus; hypertension; obesity; prevalence; the metabolic syndrome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; METOPROLOL; NIFEDIPINE; PINDOLOL; PROPRANOLOL; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MEDLINE; METABOLIC SYNDROME X; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PREDICTOR VARIABLE; PREVALENCE; RETINOPATHY; RISK; STROKE;

EID: 36148961623     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.07.010     Document Type: Article

References (21)

1. Zimmet P., Alberti K., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. Eberwine D. Globesity: A crisis of growing proportions. Diabetes Voice 48 (2003) 30-33
3. Rathmann W., Haastert B., et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000. Diabetologia 46 (2003) 182-189
4. Chobanian A., Bakris G., Black H., et al., for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
5. Wolf-Maier K., Cooper R., Banegas J., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289 (2003) 2363-2369
6. Haffner S., Lehto S., Ronnemaa T., et al. MortaliW from coronary heart disease in subjects with Wpe 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
7. Diabetes Research Working Group. Conquering Diabetes: A Strategic Plan for the 21st Century. Bethesda, Md: National Institutes of Health, US Dept of Health and Human Services. NIH publication No. 99-4398 (February 1999)
8. Liszka H., Mainous III A., King D., et al. Prehypertension and cardiovascular morbidity. Ann Farn Med 3 (2005) 294-299
9. Qureshi A., Suri M., Kirmani J., et al. Is prehypertension a risk factor for cardiovascular diseases?. Stroke 36 (2005) 1859-1863
10. Kahn R., Buse J., Ferranini E., et al., for the European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
11. Eckel R., Grundy S., and Zimmet P. The metabolic syndrome. Lancet 365 (2005) 1415-1428
12. Nilsson P. Hypertension and diabetes mellitus. In: Pickup J., and Williams G. (Eds). Textbook of Diabetes. 2nd ed (1997), Blackwell Science, Oxford, United Kingdom 56.1-56.19
13. Schernthaner G., Ritz E., Philipp T., and Bretzel R. Night time blood pressure in diabetic patients-the submerged portion of the iceberg?. Nephrol Dial Transplant 14 (1999) 1061-1064
14. Sturrock N., Pound N., Peck G., et al. An assessment of blood pressure measurement in a diabetic clinic using random-zero, semi-automated, and 24-hour monitoring. Diabet Med 14 (1997) 370-375
15. Equiluz-Bruck S., Schnack C., Kopp H., and Schernthaner G. Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus. Am J Hypertens 9 (1996) 1139-1143
16. Nakano S., Fukuda M., Hotta F., et al. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 47 (1998) 1501-1506
17. Berne C., Pollare T., and Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14 Suppl 4 (1991) 39-47
18. Gress T., Nieto F., Shahar E., et al., for the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 342 (2000) 905-912
19. Abuissa H., Jones P., Marso S., and O'Keefe Jr. J. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. A meta-analysis of randomized clinical trials. J Am Coil Cardiol 46 (2005) 821-826
20. Williams B. Recent hypertension trials: Implications and controversies. J Am Coll Cardiol 45 (2005) 813-827
21. Dahlof B., Sever P., Poulter N., et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366 (2005) 895-906